Serum Concentration of Cystatin C and Risk of End-Stage Renal Disease in Diabetes
Open Access
- 13 October 2012
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 35 (11), 2311-2316
- https://doi.org/10.2337/dc11-2220
Abstract
OBJECTIVE Patients with diabetes have a high risk of end-stage renal disease (ESRD). We examined whether prediction of this outcome, according to chronic kidney disease (CKD) staging by creatinine-based estimates of the glomerular filtration rate (eGFRcreat), is improved by further staging with serum cystatin C–based estimates (eGFRcyst). RESEARCH DESIGN AND METHODS Patients with diabetes in CKD stages 1–3 were selected from three cohorts: two from Joslin Diabetes Center, one with type 1 diabetes (N = 364) and one with type 2 diabetes (N = 402), and the third from the Finnish Diabetic Nephropathy (FinnDiane) Study of type 1 (N = 399). Baseline serum concentrations of creatinine and cystatin C were measured in all patients. Follow-up averaged 8–10 years and onsets of ESRD (n = 246) and death unrelated to ESRD (n = 159) were ascertained. RESULTS Although CKD staging by eGFRcyst was concordant with that by eGFRcreat for 62% of Joslin patients and 73% of FinnDiane patients, those given a higher stage by eGFRcyst than eGFRcreat had a significantly higher risk of ESRD than those with concordant staging in all three cohorts (hazard ratio 2.3 [95% CI 1.8–3.1]). Similarly, patients at a lower stage by eGFRcyst than by eGFRcreat had a lower risk than those with concordant staging (0.30 [0.13–0.68]). Deaths unrelated to ESRD followed the same pattern, but differences were not as large. CONCLUSIONS In patients with diabetes, CKD staging based on eGFRcyst significantly improves ESRD risk stratification based on eGFRcreat. This conclusion can be generalized to patients with type 1 and type 2 diabetes and to diabetic patients in the U.S. and Finland.Keywords
This publication has 21 references indexed in Scilit:
- Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 DiabetesJournal of the American Society of Nephrology, 2012
- Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Cystatin C Equations for Estimating GFR With Standardized Serum Cystatin C ValuesAmerican Journal of Kidney Diseases, 2011
- Estimated GFR Associates with Cardiovascular Risk Factors Independently of Measured GFRJournal of the American Society of Nephrology, 2011
- Competing-Risk Analysis of ESRD and Death among Patients with Type 1 Diabetes and MacroalbuminuriaJournal of the American Society of Nephrology, 2011
- Risk for ESRD in Type 1 Diabetes Remains High Despite RenoprotectionJournal of the American Society of Nephrology, 2011
- Cystatin C Identifies Chronic Kidney Disease Patients at Higher Risk for ComplicationsJournal of the American Society of Nephrology, 2011
- Cystatin C is not a better estimator of GFR than plasma creatinine in the general populationKidney International, 2010
- Estimating GFR Using Serum Cystatin C Alone and in Combination With Serum Creatinine: A Pooled Analysis of 3,418 Individuals With CKDAmerican Journal of Kidney Diseases, 2008
- Can Cystatin C Replace Creatinine to Estimate Glomerular Filtration Rate? A Literature ReviewAmerican Journal of Nephrology, 2007
- Metabolic Syndrome in Type 1 DiabetesDiabetes Care, 2005